Affimed's common shares are listed on the NASDAQ Capital Market under the symbol AFMD. Who is Affimed's transfer agent? American Stock Transfer and Trust ...
Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024 ... Affimed to Host Investor Conference Call Highlighting Clinical Data ...
People also ask
When did Affimed go public?
Find the latest Affimed N.V. (AFMD) annual income ... Investor Relations Intelligence. Featured ... Start browsing Stocks, Funds, ETFs and more asset classes. /.
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies. Its lead candidate is AFM13, ...
See the company profile for Affimed N.V. (AFMD) ... Affimed N.V. (AFMD). Follow. 5.37 -0.12 (-2.19%). At ... Head of Investor Relations & Director of Investor ...
Mar 6, 2024 · ... Investor Relations website, https://www.affimed.com/investors/. About Affimed N.V.. Affimed (Nasdaq: AFMD) is a clinical-stage immuno ...
This information can be used by investors to verify and understand the financial position of the company. Many, but not all SEC filings are available in the ...
Affimed N.V. (NASDAQ:AFMD) Q4 2023 Earnings Call Transcript
finance.yahoo.com › news › affimed-n-v...
Apr 1, 2024 · Affimed N.V. (NASDAQ:AFMD) Q4 2023 Earnings Call Transcript March 28, 2024 Affimed N.V. isn't one of the 30 most popular stocks among hedge ...
In depth view into AFMD (Affimed) stock including ... Affimed NV (AFMD). 5.12 +0.13 (+2.61%) USD | NASDAQ ... Investor Relations URL, https://www.affimed.com ...
Jun 17, 2022 · Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects.
Missing: relations | Show results with:relations